138 related articles for article (PubMed ID: 17493350)
1. [Ex vivo expansion of highly purified NK cells from human peripheral blood].
Li XH; Ma J; Wang FF; Dou LP; Li M; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):373-7. PubMed ID: 17493350
[TBL] [Abstract][Full Text] [Related]
2. [Method for expansion in vitro of CD3-CD56+CD16+NK cells highly purified from human peripheral blood].
Xiong D; Yang ZG; Li QH; Wu ZC; Lü JT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1310-5. PubMed ID: 21129283
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo expansion of natural killer cells for clinical applications.
Klingemann HG; Martinson J
Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
[TBL] [Abstract][Full Text] [Related]
4. [Effect of various combinations of IL2, IL12 and IL15 on function of human peripheral blood derived NK cells].
Li XH; Ma J; Wu XX; Li M; Wang FF; DA WM; Yu L; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):918-23. PubMed ID: 19698229
[TBL] [Abstract][Full Text] [Related]
5. [Expansion of CIK/NK cells from cord blood by using different combinations of stem cell factor, FLT3 ligand and interleukin 2, 7, 15 in vitro].
Li Y; Huang SL; Wu YF; Wei J; Bao R; Zhou DH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):350-4. PubMed ID: 15228665
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Tam YK; Martinson JA; Doligosa K; Klingemann HG
Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo expansion of T, NK and CD34+ cells from umbilical cord blood.
Wei YM; Cao Q; Zhou HY; Xia R; Lan JC; Meng FY; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1076-81. PubMed ID: 16403284
[TBL] [Abstract][Full Text] [Related]
8. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
[TBL] [Abstract][Full Text] [Related]
9. Availability of NK cell expansion agent combined with recombinant IL‑2 and IL‑15 stimulation on the expansion and high‑purity of NK cells in patients with immune‑related pancytopenia in vitro.
Li Y; Liu B; Ding S; Liu C; Chen T; Li L; Shao Z; Fu R
Mol Med Rep; 2019 Nov; 20(5):4358-4366. PubMed ID: 31545423
[TBL] [Abstract][Full Text] [Related]
10. [Expansion of human natural killer cells ex vivo].
Huang QS; Li Q; Huang Y; Shang P; Zhang MJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Dec; 24(12):1167-9. PubMed ID: 19068202
[TBL] [Abstract][Full Text] [Related]
11. Differential expansion of umbilical cord blood mononuclear cell-derived natural killer cells dependent on the dose of interleukin-15 with Flt3L.
Nagamura-Inoue T; Mori Y; Yizhou Z; Watanabe N; Takahashi TA
Exp Hematol; 2004 Feb; 32(2):202-9. PubMed ID: 15102482
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers.
Kim EK; Ahn YO; Kim S; Kim TM; Keam B; Heo DS
Cytotherapy; 2013 Feb; 15(2):231-241.e1. PubMed ID: 23321334
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and function.
Sotiriadou NN; Perez SA; Gritzapis AD; Mahaira LG; Salagianni M; Baxevanis CN; Papamichail M
Cell Immunol; 2005 Mar; 234(1):67-75. PubMed ID: 16024007
[TBL] [Abstract][Full Text] [Related]
14. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.
Decot V; Voillard L; Latger-Cannard V; Aissi-Rothé L; Perrier P; Stoltz JF; Bensoussan D
Exp Hematol; 2010 May; 38(5):351-62. PubMed ID: 20172016
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
[TBL] [Abstract][Full Text] [Related]
16. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
17. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
18. [Expression of perforin in cord blood NK cells after IL-2/IL-15 stimulation and its relation with cytotoxicity].
Wu YF; Zhang BH; Cen DY; Wei J; Chen C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1015-8. PubMed ID: 21867635
[TBL] [Abstract][Full Text] [Related]
19. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.
Perussia B; Ramoni C; Anegon I; Cuturi MC; Faust J; Trinchieri G
Nat Immun Cell Growth Regul; 1987; 6(4):171-88. PubMed ID: 2960890
[TBL] [Abstract][Full Text] [Related]
20. Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies.
Hoogduijn MJ; Roemeling-van Rhijn M; Korevaar SS; Engela AU; Weimar W; Baan CC
Hum Gene Ther; 2011 Dec; 22(12):1587-91. PubMed ID: 21732766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
